Diagnostics
Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in…
Read More
Findings from the GUARDIAN-Lung Registry highlight statistically significant reductions in hospital readmissions and acute rejection rates with advanced hypothermic lung preservation technologies Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45th ISHLT Annual Meeting and Scientific Sessions.…
Read More
Excerpt from the Press Release: FOSTER CITY, Calif. and DURHAM, N.C., April 24, 2025 /PRNewswire/ — 1Cell.Ai, a global leader in single cell precision diagnostics, has joined forces with BioSkryb Genomics, a pioneer in single cell multi-omics, to co-develop and commercialize next-generation single cell multi-omic solutions. This collaboration will empower researchers and clinicians to detect…
Read More
Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head…
Read More
Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Feb. 14, 2025– Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)…
Read More
Presentation highlights preclinical profile for HST-1021, a highly differentiated potent, selective, and potential first-in-class MALT1 scaffolding inhibitor Excerpt from the Press Release: BOSTON, June 20, 2024 /PRNewswire/ — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,”…
Read More
Excerpt from the Press Release: BERKELEY, Calif. and MAINZ, Germany, April 25, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today groundbreaking topline results from a pooled clinical study which included new patients and subjects from Mainz…
Read More
Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Excerpt from the Press Release: BOSTON, March 21, 2024 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham…
Read More
Excerpt from the Press Release: LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201). Based on the Company’s interactions with the U.S. Food and Drug Administration (FDA), the Company…
Read More
Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov. 7, 2023– Veracyte, Inc. (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing…
Read More